文献速递头颈与中枢神经肿瘤

瑞戈非尼对比洛莫司汀治疗复发胶质母细胞瘤(REGOMA):一项多中心、开放标签、随机对照2期试验

Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial.
PubMed 文献 · Lancet Oncol · 2018-12-03

REGOMA是在意大利10个中心开展的随机、多中心、开放标签2期试验,纳入119例复发胶质母细胞瘤患者,按1:1随机接受瑞戈非尼160 mg(每4周周期前3周每日一次)或洛莫司汀110 mg/m²(每6周一次)。瑞戈非尼组中位总生存7.4个月(95%CI 5.8-12.0),洛莫司汀组5.6个月(4.7-7.3),HR 0.50(95%CI 0.33-0.75),log-rank p=0.0009。

要点

  • 复发胶质母细胞瘤患者中,瑞戈非尼组中位总生存7.4个月,洛莫司汀组5.6个月,HR 0.50(95%CI 0.33-0.75),log-rank p=0.0009。
  • 瑞戈非尼组3-4级治疗相关不良事件33例(56%),洛莫司汀组24例(40%)。
  • 作者认为瑞戈非尼显示出令人鼓舞的总生存获益,可能成为新的潜在治疗选择,并应在样本量充足的3期研究中进一步研究。

核心结论

  • REGOMA显示瑞戈非尼在复发胶质母细胞瘤中具有令人鼓舞的总生存获益。
  • 作者认为该药可能是这些患者的一种新的潜在治疗选择,并应在样本量充足的3期研究中进行研究。

研究设计与样本

  • REGOMA是一项在意大利10个中心开展的随机、多中心、开放标签2期试验。
  • 纳入年龄≥18岁、组织学确诊胶质母细胞瘤、ECOG体能状态0或1、手术后放化疗(替莫唑胺同步放化疗)后记录到疾病进展的患者。
  • 采用网络系统按1:1随机分组,按中心和复发时是否手术(是 vs 否)分层。
  • 瑞戈非尼组给予瑞戈非尼160 mg,每4周周期的前3周每日一次;洛莫司汀组给予洛莫司汀110 mg/m²,每6周一次;治疗持续至疾病进展、死亡、不可接受毒性或撤回知情同意。
  • 主要终点为意向治疗人群的总生存;2015年11月27日至2017年2月23日筛查124例,119例合格患者随机分配至瑞戈非尼组(n=59)或洛莫司汀组(n=60)。

主要发现

  • 中位随访15.4个月(IQR 13.8-18.1);截至分析截点,119例中99例(83%)死亡,瑞戈非尼组59例中42例(71%),洛莫司汀组60例中57例(95%)。
  • 瑞戈非尼组中位总生存7.4个月(95%CI 5.8-12.0),洛莫司汀组5.6个月(95%CI 4.7-7.3),HR 0.50(95%CI 0.33-0.75),log-rank p=0.0009。
  • 3-4级治疗相关不良事件:瑞戈非尼组59例中33例(56%),洛莫司汀组60例中24例(40%)。
  • 瑞戈非尼组最常见的3或4级不良事件为手足皮肤反应、脂肪酶升高和血胆红素升高,各为59例中6例(10%)。
  • 洛莫司汀组最常见的3或4级不良事件为血小板计数降低(60例中8例[13%])、淋巴细胞计数降低(60例中8例[13%])和中性粒细胞减少(60例中7例[12%]);研究者认为无死亡与药物相关。

关键数值与推荐

  • 瑞戈非尼组中位总生存7.4个月(95%CI 5.8-12.0)vs 洛莫司汀组5.6个月(95%CI 4.7-7.3),HR 0.50(95%CI 0.33-0.75),log-rank p=0.0009。
  • 3-4级治疗相关不良事件:瑞戈非尼组56%(33/59)vs 洛莫司汀组40%(24/60)。

临床怎么用

  • 作者认为瑞戈非尼在复发胶质母细胞瘤中显示出令人鼓舞的总生存获益,可能是这些患者的一种新的潜在治疗选择。
  • 作者建议在样本量充足的3期研究中对瑞戈非尼进行进一步研究。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Glioblastoma is a highly vascularised tumour and there are few treatment options after disease recurrence. Regorafenib is an oral multikinase inhibitor of angiogenic, stromal, and oncogenic receptor tyrosine kinases. We aimed to assess the efficacy and safety of regorafenib in the treatment of recurrent glioblastoma. METHODS: REGOMA is a randomised, multicentre, open-label phase 2 trial done in ten centres in Italy. Eligible patients (aged ≥18 years) with histologically confirmed glioblastoma, Eastern Cooperative Oncology Group performance status 0 or 1, and documented disease progression after surgery followed by radiotherapy and temozolomide chemoradiotherapy were randomly assigned (1:1) by a web-based system, stratified by centre and surgery at recurrence (yes vs no), to receive regorafenib 160 mg once daily for the first 3 weeks of each 4-week cycle or lomustine 110 mg/m2 once every 6 weeks until disease progression, death, unacceptable toxicity, or consent withdrawal. The primary endpoint was overall survival in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, NCT02926222, and is currently in follow-up. FINDINGS: Between Nov 27, 2015, and Feb 23, 2017, 124 patients were screened and 119 eligible patients were randomly assigned to receive regorafenib (n=59) or lomustine (n=60). Median follow-up was 15·4 months (IQR 13·8-18·1). At the analysis cutoff date, 99 (83%) of 119 patients had died: 42 (71%) of 59 in the regorafenib group and 57 (95%) of 60 in the lomustine group. Overall survival was significantly improved in the regorafenib group compared with the lomustine group, with a median overall survival of 7·4 months (95% CI 5·8-12·0) in the regorafenib group and 5·6 months (4·7-7·3) in the lomustine group (hazard ratio 0·50, 95% CI 0·33-0·75; log-rank p=0·0009). Grade 3-4 treatment-related adverse events occurred in 33 (56%) of 59 patients treated with regorafenib and 24 (40%) of 60 with lomustine. The most frequent grade 3 or 4 adverse events related to regorafenib were hand-foot skin reaction, increased lipase, and blood bilirubin increased (in six [10%] of 59 patients each). In the lomustine group, the most common grade 3 or 4 adverse events were decreased platelet count (eight [13%] of 60 patients), decreased lymphocyte count (eight [13%]), and neutropenia (seven [12%]). No death was considered by the investigators to be drug related. INTERPRETATION: REGOMA showed an encouraging overall survival benefit of regorafenib in recurrent glioblastoma. This drug might be a new potential treatment for these patients and should be investigated in an adequately powered phase 3 study. FUNDING: Veneto Institute of Oncology and Bayer Italy.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Lombardi G, De Salvo GL, Brandes AA, et al. Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol. 2018. PMID: 30522967. doi:10.1016/S1470-2045(18)30675-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。